Annual Report

Overview

The report describes Opthea's lead drug candidate sozinibercept progressing through global Phase 3 wet AMD trials, with approximately 75% enrollment reported in August 2023. It presents ESG reporting around four pillars and explicitly adopts double materiality. It also reports FY23 Scope 1 and 2 CO2-e emissions of 4.24 tonnes.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: Ends 30 June 2023
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services